Home » Invitrogen, ABI Merger Valued at $5.1 Billion

Invitrogen, ABI Merger Valued at $5.1 Billion

Jan 23, 2009

NEW YORK (GenomeWeb News) – The November merger of Invitrogen and Applied Biosystems to form Life Technologies has been valued at $5.1 billion, down from the initial estimate of $6.7 billion.

Life Technologies disclosed in a filing with the US Securities and Exchange Commission yesterday that the value of Life Technologies shares issued in the transaction was around $1.8 billion, while the cash portion of the deal was roughly $3.2 billion. ABI shareholders received a total of approximately 80.8 million of the combined company's shares.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Scan

Helix Launches 'App Store'

Helix customers can purchase apps that interpret different aspects of their genome, Technology Review reports.

More CAR-T Therapies Sought

The New York Times reports that a number of companies and research institutes are pursuing gene therapies.

Telomeres of Spawning Salmon

Salmon with shorter telomeres survive to make the trip back to their river homes, New Scientist reports.

This Week in PLOS

In PLOS this week: vaginal microbiome composition, population patterns of Chagas-carrying Rhodnius ecuadoriensis, and more.

Sponsorships

Privacy Policy.  Copyright © 2017 GenomeWeb LLC.  All Rights Reserved.